bet bromodomain inhibitor zen-3694
bet bromodomain inhibitor zen-3694: 9 clinical trials tracked.
bet bromodomain inhibitor zen-3694 evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about bet bromodomain inhibitor zen-3694, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (9)
A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)
Primary endpoint: Clinical/radiographic progression free survival (PFS) with BATZEN
A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer
Primary endpoint: Maximum tolerated dose (dose escalation cohort)
Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors
Primary endpoint: Incidence of adverse events
A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer
Primary endpoint: Maximum tolerated dose (MTD) of ZEN003694 (ZEN-3694) used in combination with pembrolizumab and nab-paclitaxel
Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer
Primary endpoint: Objective Response
A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer
Primary endpoint: Incidence of dose limiting toxicities (Part 1 [Dose Escalation])
A Phase 1 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Platinum-based Chemotherapy in Patients With NUT Carcinoma
Primary endpoint: Maximum tolerated dose (MTD) (phase 1)
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Composite Response Rate
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Primary endpoint: Incidence of treatment-related adverse events (AE) and treatment-related serious adverse events (SAE)